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Introduction
Non infectious uveitis in childhood is a relatively uncom-
mon severe disease, with potential significant long-term
complications such as cataract, glaucoma and eventually
blindness. For these reasons refractory uveitis usually
requires early and aggressive immunosuppressive treat-
ment in order to preserve visual acuity and to prevent the
significant morbidity of chronic steroid administration.
However, the lack of evidence from head-to-head
randomized controlled trials (RCT) limits our understand-
ing about the best treatment choices, as well as time of
instituting therapy and its duration. Once a child with
active uveitis has achieved remission on treatment, there
are no evidence-based guidelines with respect to the dura-
tion of continued treatment in autoimmune child chronic
uveitis. Information regarding the natural clinical history
of a child on systemic treatment due to auto-immune
chronic uveitis would be helpful in driving therapy: if it
would be possible to identify early children at high risk to
flare once systemic therapy is stopped, they could have
benefits in visual acuity prognosis and quality of life, as
well as time free from disease.
Objectives
Aim of our study was to assess the time on remission
after discontinuing systemic therapy in a retrospective,
comparative, multi-centre, cohort study of childhood
non-infectious chronic uveitis.
Methods
39 patients (29 F, 10 M; median age: 11.6 years, 31 JIA,
8 Idiopathic Chronic Uveitis [IdCU]) from 4 different
paediatric rheumatology centres, with previously refrac-
tory, vision threatening, non-infectious inactive uveitis,
which discontinued all related treatments for at least
3 months were enrolled. 23 children previously received
Methotrexate, 16 TNF inhibitors. Primary outcome was
to assess, once remission was achieved, the time on
remission up to the first relapse after discontinuing
treatment. Time to remission once systemic not-steroid
treatment was started, time to steroid discontinuation,
number of relapses before achieving remission and time
on remission on therapy before discontinuing all treat-
ments were also considered.
Results
Median follow-up time on remission without treatment
was 9 months (range 1–59 months). At last available
follow-up after 1 year from discontinuation of treatment
[49 months, range 15-168], 11/39 (28.2%) children main-
tained a complete remission over a median period of
18 months. At 49 months of follow-up, 6/8 children with
IdCU (75%) compared to 5/31 children with JIA (16.1%)
were still on remission without treatment (p<0.003).
A higher probability of maintaining uveitis remission after
discontinuing treatment was shown in IdCU compared to
JIA group (Mantel-Cox c2 7.62, p<0.006). ANA positivity
was associated with a higher probability of flare in overall
population (Mantel-Cox c2 6.68, p<0.01), in ICU, but not
in sub-analysis limited to JIA (Mantel-Cox c2 0.78,
p=0.37) and IdCU (Mantel-Cox c2 1.18, p=0.27). None
clinical variable, including time on remission on therapy,
total length of treatment, and type of treatment, resulted
significant predictors of long-lasting remission without
therapy.
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Conclusion
Even if limited to a relatively small group in retrospectively
study design, our results suggest that type of disease,
rather than the type or the length of treatment, can predict
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